vs
Apellis Pharmaceuticals, Inc.（APLS）与TIDEWATER INC（TDW）财务数据对比。点击上方公司名可切换其他公司
TIDEWATER INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$336.8M vs $199.9M），TIDEWATER INC净利率更高（65.3% vs -29.5%，领先94.8%），TIDEWATER INC同比增速更快（-2.4% vs -5.9%），TIDEWATER INC自由现金流更多（$147.8M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Tidewater Inc.是一家公开上市的国际石油服务企业，总部位于美国得克萨斯州休斯敦。公司运营专业船舶船队，主要为海上油气、海上风电行业提供船舶租赁及相关海事服务，是全球海洋能源服务领域的重要参与者。
APLS vs TDW — 直观对比
营收规模更大
TDW
是对方的1.7倍
$199.9M
营收增速更快
TDW
高出3.5%
-5.9%
净利率更高
TDW
高出94.8%
-29.5%
自由现金流更多
TDW
多$162.1M
$-14.3M
两年增速更快
APLS
近两年复合增速
2.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $336.8M |
| 净利润 | $-59.0M | $219.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 19.0% |
| 净利率 | -29.5% | 65.3% |
| 营收同比 | -5.9% | -2.4% |
| 净利润同比 | -62.2% | 495.8% |
| 每股收益（稀释后） | $-0.40 | $4.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTDW
| Q4 25 | $199.9M | $336.8M | ||
| Q3 25 | $458.6M | $341.1M | ||
| Q2 25 | $178.5M | $341.4M | ||
| Q1 25 | $166.8M | $333.4M | ||
| Q4 24 | $212.5M | $345.1M | ||
| Q3 24 | $196.8M | $340.4M | ||
| Q2 24 | $199.7M | $339.2M | ||
| Q1 24 | $172.3M | $321.2M |
净利润APLSTDW
| Q4 25 | $-59.0M | $219.9M | ||
| Q3 25 | $215.7M | $-806.0K | ||
| Q2 25 | $-42.2M | $72.9M | ||
| Q1 25 | $-92.2M | $42.7M | ||
| Q4 24 | $-36.4M | $36.9M | ||
| Q3 24 | $-57.4M | $46.4M | ||
| Q2 24 | $-37.7M | $50.4M | ||
| Q1 24 | $-66.4M | $47.0M |
营业利润率APLSTDW
| Q4 25 | -25.6% | 19.0% | ||
| Q3 25 | 48.7% | 18.4% | ||
| Q2 25 | -18.6% | 23.7% | ||
| Q1 25 | -50.0% | 22.5% | ||
| Q4 24 | -12.3% | 23.6% | ||
| Q3 24 | -24.0% | 20.6% | ||
| Q2 24 | -14.7% | 23.0% | ||
| Q1 24 | -36.0% | 25.5% |
净利率APLSTDW
| Q4 25 | -29.5% | 65.3% | ||
| Q3 25 | 47.0% | -0.2% | ||
| Q2 25 | -23.6% | 21.4% | ||
| Q1 25 | -55.3% | 12.8% | ||
| Q4 24 | -17.1% | 10.7% | ||
| Q3 24 | -29.2% | 13.6% | ||
| Q2 24 | -18.9% | 14.8% | ||
| Q1 24 | -38.5% | 14.6% |
每股收益（稀释后）APLSTDW
| Q4 25 | $-0.40 | $4.37 | ||
| Q3 25 | $1.67 | $-0.02 | ||
| Q2 25 | $-0.33 | $1.46 | ||
| Q1 25 | $-0.74 | $0.83 | ||
| Q4 24 | $-0.30 | $0.70 | ||
| Q3 24 | $-0.46 | $0.87 | ||
| Q2 24 | $-0.30 | $0.94 | ||
| Q1 24 | $-0.54 | $0.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $578.8M |
| 总债务越低越好 | — | $670.1M |
| 股东权益账面价值 | $370.1M | $1.4B |
| 总资产 | $1.1B | $2.4B |
| 负债/权益比越低杠杆越低 | — | 0.49× |
8季度趋势，按日历期对齐
现金及短期投资APLSTDW
| Q4 25 | $466.2M | $578.8M | ||
| Q3 25 | $479.2M | $428.2M | ||
| Q2 25 | $370.0M | $369.4M | ||
| Q1 25 | $358.4M | $341.8M | ||
| Q4 24 | $411.3M | $324.9M | ||
| Q3 24 | $396.9M | $280.8M | ||
| Q2 24 | $360.1M | $315.9M | ||
| Q1 24 | $325.9M | $280.9M |
总债务APLSTDW
| Q4 25 | — | $670.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $647.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSTDW
| Q4 25 | $370.1M | $1.4B | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $1.1B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.1B | ||
| Q1 24 | $266.7M | $1.1B |
总资产APLSTDW
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $821.4M | $2.1B | ||
| Q1 25 | $807.3M | $2.1B | ||
| Q4 24 | $885.1M | $2.1B | ||
| Q3 24 | $901.9M | $2.0B | ||
| Q2 24 | $904.5M | $2.1B | ||
| Q1 24 | $831.9M | $2.1B |
负债/权益比APLSTDW
| Q4 25 | — | 0.49× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $153.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $147.8M |
| 自由现金流率自由现金流/营收 | -7.1% | 43.9% |
| 资本支出强度资本支出/营收 | 0.1% | 1.5% |
| 现金转化率经营现金流/净利润 | — | 0.70× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $353.3M |
8季度趋势，按日历期对齐
经营现金流APLSTDW
| Q4 25 | $-14.2M | $153.0M | ||
| Q3 25 | $108.5M | $54.7M | ||
| Q2 25 | $4.4M | $85.4M | ||
| Q1 25 | $-53.4M | $86.0M | ||
| Q4 24 | $19.4M | $100.0M | ||
| Q3 24 | $34.1M | $49.0M | ||
| Q2 24 | $-8.3M | $78.6M | ||
| Q1 24 | $-133.0M | $54.8M |
自由现金流APLSTDW
| Q4 25 | $-14.3M | $147.8M | ||
| Q3 25 | $108.3M | $49.6M | ||
| Q2 25 | $4.4M | $80.2M | ||
| Q1 25 | $-53.4M | $75.7M | ||
| Q4 24 | $19.3M | $95.5M | ||
| Q3 24 | — | $43.3M | ||
| Q2 24 | $-8.4M | $72.3M | ||
| Q1 24 | $-133.3M | $43.8M |
自由现金流率APLSTDW
| Q4 25 | -7.1% | 43.9% | ||
| Q3 25 | 23.6% | 14.5% | ||
| Q2 25 | 2.5% | 23.5% | ||
| Q1 25 | -32.0% | 22.7% | ||
| Q4 24 | 9.1% | 27.7% | ||
| Q3 24 | — | 12.7% | ||
| Q2 24 | -4.2% | 21.3% | ||
| Q1 24 | -77.3% | 13.6% |
资本支出强度APLSTDW
| Q4 25 | 0.1% | 1.5% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 3.1% | ||
| Q4 24 | 0.0% | 1.3% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 1.9% | ||
| Q1 24 | 0.2% | 3.4% |
现金转化率APLSTDW
| Q4 25 | — | 0.70× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.71× | ||
| Q3 24 | — | 1.06× | ||
| Q2 24 | — | 1.56× | ||
| Q1 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TDW
暂无分部数据
